A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia

Aref Al‐Kali, Ibrahim Aldoss, Pamela J Atherton, Carrie A Strand, Bijal Shah, Jonathan Webster, Bhavana Bhatnagar, Karen S Flatten, Kevin L Peterson, Paula A Schneider, Sarah A Buhrow, Jianping Kong, Joel M Reid, Alex A Adjei, Scott H Kaufmann · 2023

Read A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia by Aref Al‐Kali, Ibrahim Aldoss, Pamela J Atherton, Carrie A Strand, Bijal Shah, Jonathan Webster, Bhavana Bhatnagar, Karen S Flatten, Kevin L Peterson, Paula A Schneider, Sarah A Buhrow, Jianping Kong, Joel M Reid, Alex A Adjei, Scott H Kaufmann (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10726920.txt.

Description

A peer-reviewed research article from Europe PMC (2023). BackgroundDespite recent approval of several new agents, relapsed acute lymphoblastic leukemia (ALL) remains challenging to treat. Sapanisertib (MLN0128/TAK‐228) is an oral TORC1/2 inhibitor that exhibited preclinical activity against ALL.MethodsWe conducted a single‐arm multi‐center Phase II study of sapanisertib monotherapy (3 mg orally daily of the milled formulation for 21 days every 28 days) in patients with ALL through the Experimental Therapeutics Clinical Trials Network (NCI‐9775).ResultsSixteen patients, 15 of whom were previously treated (median 3 prior lines of therapy), were enrolled.

Catalog record

CREATORAref Al‐Kali, Ibrahim Aldoss, Pamela J Atherton, Carrie A Strand, Bijal Shah, Jonathan Webster, Bhavana Bhatnagar, Karen S Flatten, Kevin L Peterson, Paula A Schneider, Sarah A Buhrow, Jianping Kong, Joel M Reid, Alex A Adjei, Scott H Kaufmann
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE34 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10726920

Browse the full library · About the Tower of Babel